Fig. 1
From: Tumor-associated myeloid cells in cancer immunotherapy
The origin and regulatory mechanism of classical TAMCs. Normally, there is a steady-state myelopoiesis in the bone marrow, producting mature erythrocytes, lymphocytes, and myeloid cells. However, tumors induce myeloid-biased differentiation via upregulation of some transcription factors and action of various regulatory factors. On the basis of downregulating CLP ratio, GMP level increases significantly and immature myeloid cells accumulate in the bone marrow